Instil Bio: ImmuneOnco reports results from Phase 2 study of IMM2510/AXN-2510

Instil Bio (TIL) noted that ImmuneOnco Biopharmaceuticals announced preliminary safety and efficacy data from the Phase 2 open-label, multicenter study of IMM2510/AXN-2510 in combination with chemotherapy for front-line patients with advanced non-small cell lung cancer conducted in China by ImmuneOnco. As of July 1, 2025, 33 patients were dosed at 10 mg/kg, with 21 patients having at least one tumor assessment. Partial responses were observed in 62% of efficacy evaluable patients, comprising partial responses in 80% of patients with squamous NSCLC and 46% of patients with non-squamous NSCLC. The majority of efficacy evaluable patients had only one tumor assessment at data cut-off. ImmuneOnco expects to present safety and efficacy data in the ‘2510 chemotherapy combination trial in front-line NSCLC at a future medical conference. The ‘2510 safety profile supports further clinical development, with no dose-limiting toxicities observed in the 33 safety evaluable patients. In these patients, there were no treatment-related adverse events leading to dose reduction or death, and only one TRAE leading to drug discontinuation. The most common Grade 3+ TRAEs were hematologic, with uncommon clinical sequelae. Adverse events typically associated with VEGF inhibition and immune-related adverse events were uncommon and generally low-grade, and infusion-related reactions were nearly all low-grade.